A+ A A- Skip to main content

Asian Paints

2282.4 96.20

Cipla

1215.9 13.50

Eicher Motors

7131 525.50

Nestle India

1213.7 -9.10

Grasim Inds

2756.2 135.20

Hindalco Inds.

951.8 -2.70

Hind. Unilever

2145.6 35.00

ITC

302.45 4.00

Trent

3905 82.00

Larsen & Toubro

4005.9 282.60

M & M

3210.1 203.50

Reliance Industries

1347.8 43.20

Tata Consumer

1068.5 6.50

Tata Motors PVeh

334.75 26.05

Tata Steel

204.18 6.05

Wipro

203.42 -1.30

Apollo Hospitals

7401.5 75.00

Dr Reddy's Labs

1191.4 -4.70

Titan Company

4492.5 261.90

SBI

1061.45 31.05

Shriram Finance

1023.2 92.55

Bharat Electron

433.1 5.30

Kotak Mah. Bank

380.15 17.20

Infosys

1346.2 6.80

Bajaj Finance

915.05 59.95

Adani Enterp.

2043.8 161.70

Sun Pharma.Inds.

1714.6 -3.40

JSW Steel

1194.3 42.40

HDFC Bank

816.1 44.10

TCS

2559.2 19.40

ICICI Bank

1309.2 63.70

Power Grid Corpn

294.85 -0.55

Maruti Suzuki

13602 804.00

Axis Bank

1333 82.90

HCL Technologies

1461 19.40

O N G C

285.5 -1.15

NTPC

374.15 5.30

Coal India

449.25 -13.75

Bharti Airtel

1861.6 31.30

Tech Mahindra

1451.4 -22.00

Jio Financial

246.86 11.53

Adani Ports

1453.3 72.30

HDFC Life Insur.

598.3 16.60

SBI Life Insuran

1907.6 66.20

Max Healthcare

941.15 8.75

UltraTech Cem.

11603 667.00

Bajaj Auto

9366 316.50

Bajaj Finserv

1784.6 100.20

Interglobe Aviat

4615.5 346.70

Eternal

243.62 11.65

Corporate News - Detailed News Back
Lupin receives USFDA approval for Dapagliflozin and Metformin Hydrochloride XR Tablets
08-Apr-26   19:18 Hrs IST
Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg. The company also received tentative approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 2.5 mg/1,000 mg.

The U.S. FDA has approved Lupin's Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets as bioequivalent to Xigduo' XR for the indications in the approved labeling.


DJIA 46614.19
-76.70 -0.16%
S&P 500 6639.23
6.40 0.10%
HANG SENG 25893.03
776.49 3.09%
NIKKEI 225 56345.93
2916.37 5.46%
FTSE 100 10596.41
247.62 2.39%
NIFTY 23997.35
873.70 3.78%
×
Ask Your Question
close
refresh